When can pharmaceutical companies communicate health economic claims to payers? 10 case studies von Neumann, P.J, Saret, C.J

Volltext

Do formulary drug exclusion policies always save money? A literature review von Chambers, J, Rane, P.B, Neumann, P.J

Volltext

DO SPECIALTY DRUGS OFFER LARGER POPULATION HEALTH BENEFITS THAN NON-SPECIALTY DRUGS? von Thorat, T, Wilkinson, C, Chambers, J, Neumann, P.J

Volltext

Who is spending where: analysis of Healthcare spending by Medicaid and Private Payers in Massachusetts von Olchanski, N, Rane, P.B, Cohen, J.T, Neumann, P.J

Volltext

Understaning Qaly Gains Across Different Types Of Cancers And Cancer-Related Interventions von Thorat, T, Chambers, J, Neumann, P.J

Volltext

Coverage of Medical devices: is Medicare consistent with Private Payers? von Chenoweth, M.D, Chambers, J, Thorat, T, Neumann, P.J

Volltext

Willingness-to-Pay for Newborn Genetic Testing for Spinal Muscular Atrophy von Lin, P, Shi, J, Yeh, W, Neumann, P.J

Volltext

Discrepancies Between Fda Approval And Cms Coverage For Drugs And Devices von Chambers, J.D, Neumann, P.J

Volltext

Cost-Effectiveness Of Fda-Approved Cancer Drugs Since 2000 von Winn, A, Neumann, P.J

Volltext

Potential savings in Healthcare spending on “low-value” interventions: case study of Arthroscopic Knee Surgery von Rane, P.B, Olchanski, N, Saret, C.J, Cohen, J.T, Neumann, P.J

Volltext

The changing Face of the Cost-Utility Literature, 1990–2012 von Thorat, T, Shi, J, Saret, C.J, Cohen, J.T, Neumann, P.J

Volltext

Cost-Effectiveness Analysis of Innovation in Hematologic Malignancies von Lin, P.J, Winn, A, Parsons, S.K, Neumann, P.J, Cohen, J.T

Volltext

Cost-utility analyses in diabetes: A systematic review and potential gains from using economic evidence von Zhong, Y, Lin, P.J, Cohen, J.T, Winn, A, Neumann, P.J

Volltext

AVAILABILITY OF COST EFFECTIVENESS INFORMATION ON THE HIGHEST-COST DRUGS AND PROCEDURES IN THE UNITED STATES von Bungay, K, Cohen, J.T, Chambers, J, Salem, M, Ciarametaro, M, Neumann, P.J

Volltext

Time Lags From Fda Drug Approval To Publication Of Cost-Utility Analysis von Thorat, T, Chambers, J.D, Neumann, P.J

Volltext

The Cost-Effectiveness Of Positron Emission Tomography (Pet): A Systematic Review Across Multiple Indications von Cangelosi, M.J, Saunders, T, Neumann, P.J, Chambers, J.D

Volltext

Review of cost-utility analyses in Asia von Thorat, T, Lin, P.J, Neumann, P.J

Volltext

A review of cardiovascular disease health state utilities reported in cost-utility analyses 2000 – 2010 von Thorat, T, Lin, P.J, Cangelosi, M.J, Neumann, P.J

Volltext

Willingness to pay for diagnostic technologies: A review of the contingent valuation literature von Lin, P.J, Cangelosi, M.J, Lee, D.W, Neumann, P.J

Volltext

HC3 Assessing the Value of Biopharmaceuticals: Cost-Effective Innovations or Inefficient Use of Resources? von Wilson, A, Neumann, P.J

Volltext